Pfizer CEO Albert Bourla said that the company plans to submit the data to the FDA so that kids are able to get vaccinated before the next school year.
“We share the urgency to expand the authorization of our vaccine to use in younger populations and are encouraged by the clinical trial data from adolescents between the ages of 12 and 15,” Bourla said.
The study involved 2,260 individuals in the United States. 18 individuals contracted COVID-19 in the placebo group while 0 did in the vaccinated group. Furthermore, the study revealed a "robust" antibody response in the age range, even better than individuals aged 16 to 25. Infectious disease experts have stated that vaccinating children is crucial to ending the pandemic. Children make up 20 percent of the US population.
Isaac Bogoch, an infectious disease specialist responded to the announcement saying it was “wonderful news,” and a “huge step forward” in the fight against COVID. “We’re talking about improving the safety of youth activity like youth sports and youth art and youth extracurricular activities,” he said.
The US hopes to start vaccinating children in the near future so that kids can get back to school and parents can get back to work.